tiprankstipranks
Travere Therapeutics (DE:17R)
BERLIN:17R
Germany Market
17R
Travere Therapeutics
RESEARCH TOOLSreports

Travere Therapeutics (17R) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

17R Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Travere
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

17R Stock 12 Month Forecast

Average Price Target

€63.34
▲(91.94% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is €63.34 with a high forecast of €78.00 and a low forecast of €42.47. The average price target represents a 91.94% change from the last price of €33.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","79":"€79","28.75":"€28.8","45.5":"€45.5","62.25":"€62.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78.0029172,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.34125776333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€63.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.46825492,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€42.47</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,28.75,45.5,62.25,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,36.46176286153846,39.92352572307692,43.38528858461538,46.84705144615384,50.3088143076923,53.77057716923077,57.23234003076923,60.69410289230769,64.15586575384614,67.6176286153846,71.07939147692306,74.54115433846154,{"y":78.0029172,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,35.3339429048718,37.66788580974359,40.001828714615385,42.33577161948718,44.66971452435898,47.00365742923077,49.33760033410257,51.671543238974365,54.005486143846156,56.33942904871795,58.67337195358975,61.00731485846154,{"y":63.34125776333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,33.728327301538464,34.45665460307692,35.184981904615384,35.91330920615385,36.641636507692304,37.36996380923077,38.09829111076923,38.826618412307695,39.55494571384615,40.283273015384616,41.01160031692308,41.739927618461536,{"y":42.46825492,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€78.00Average Price Target€63.34Lowest Price Target€42.47
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:17R
Edward Nash
Canaccord Genuity
Canaccord Genuity
€60.67
Buy
83.85%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Immunome (NASDAQ: IMNM)
Evercore ISI Analyst forecast on DE:17R
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€58.94→€67.6
Buy
104.86%
Upside
Assigned
08/10/26
Travere Therapeutics price target raised to $78 from $68 at Evercore ISITravere Therapeutics price target raised to $78 from $68 at Evercore ISI
Stifel Nicolaus Analyst forecast on DE:17R
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€37.27→€53.74
Hold
62.83%
Upside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
J.P. Morgan Analyst forecast on DE:17R
Anupam Rama
J.P. Morgan
J.P. Morgan
€45.94→€78
Buy
136.37%
Upside
Reiterated
08/06/26
Travere Therapeutics (TVTX) Gets a Buy from J.P. Morgan
Wedbush Analyst forecast on DE:17R
Laura Chico
Wedbush
Wedbush
€52.87→€65
Buy
96.98%
Upside
Reiterated
08/06/26
Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)
Citi Analyst forecast on DE:17R
Yigal Nochomovitz
Citi
Citi
€60.67→€73.67
Buy
123.24%
Upside
Reiterated
08/06/26
Travere Therapeutics price target raised to $85 from $70 at CitiTravere Therapeutics price target raised to $85 from $70 at Citi
Wells Fargo Analyst forecast on DE:17R
Mohit Bansal
Wells Fargo
Wells Fargo
€56.34→€69.34
Buy
110.11%
Upside
Reiterated
08/06/26
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo
H.C. Wainwright Analyst forecast on DE:17R
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€58.07
Buy
75.97%
Upside
Reiterated
08/05/26
Travere Therapeutics: Buy Rating Reiterated as FILSPARI Momentum Builds and Key Catalysts Approach; Price Target Unchanged at $67
Guggenheim Analyst forecast on DE:17R
Vamil Divan
Guggenheim
Guggenheim
€56.34→€65
Buy
96.98%
Upside
Reiterated
08/05/26
Travere Therapeutics price target raised to $75 from $65 at GuggenheimTravere Therapeutics price target raised to $75 from $65 at Guggenheim
Bank of America Securities Analyst forecast on DE:17R
Jason Zemansky
Bank of America Securities
Bank of America Securities
€61.54
Buy
86.47%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:17R
Tyler Van Buren
TD Cowen
TD Cowen
€52→€65
Buy
96.98%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on DE:17R
Allison Bratzel
Piper Sandler
Piper Sandler
€42.47
Buy
28.69%
Upside
Reiterated
06/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Elanco Animal Health (NYSE: ELAN), AbSci (NASDAQ: ABSI) and Travere Therapeutics (NASDAQ: TVTX)
Cantor Fitzgerald Analyst forecast on DE:17R
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
02/20/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY), UnitedHealth (NYSE: UNH) and Travere Therapeutics (NASDAQ: TVTX)
Leerink Partners Analyst forecast on DE:17R
Joseph Schwartz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
01/13/26
Leerink says Travere's Filspari PDUFA extension removes worst case scenario Leerink says Travere's Filspari PDUFA extension removes worst case scenario
Jefferies Analyst forecast on DE:17R
Maury Raycroft
Jefferies
Jefferies
€30.33
Buy
-8.08%
Downside
Reiterated
09/10/25
AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:17R
Edward Nash
Canaccord Genuity
Canaccord Genuity
€60.67
Buy
83.85%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Immunome (NASDAQ: IMNM)
Evercore ISI Analyst forecast on DE:17R
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€58.94→€67.6
Buy
104.86%
Upside
Assigned
08/10/26
Travere Therapeutics price target raised to $78 from $68 at Evercore ISITravere Therapeutics price target raised to $78 from $68 at Evercore ISI
Stifel Nicolaus Analyst forecast on DE:17R
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€37.27→€53.74
Hold
62.83%
Upside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
J.P. Morgan Analyst forecast on DE:17R
Anupam Rama
J.P. Morgan
J.P. Morgan
€45.94→€78
Buy
136.37%
Upside
Reiterated
08/06/26
Travere Therapeutics (TVTX) Gets a Buy from J.P. Morgan
Wedbush Analyst forecast on DE:17R
Laura Chico
Wedbush
Wedbush
€52.87→€65
Buy
96.98%
Upside
Reiterated
08/06/26
Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)
Citi Analyst forecast on DE:17R
Yigal Nochomovitz
Citi
Citi
€60.67→€73.67
Buy
123.24%
Upside
Reiterated
08/06/26
Travere Therapeutics price target raised to $85 from $70 at CitiTravere Therapeutics price target raised to $85 from $70 at Citi
Wells Fargo Analyst forecast on DE:17R
Mohit Bansal
Wells Fargo
Wells Fargo
€56.34→€69.34
Buy
110.11%
Upside
Reiterated
08/06/26
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo
H.C. Wainwright Analyst forecast on DE:17R
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€58.07
Buy
75.97%
Upside
Reiterated
08/05/26
Travere Therapeutics: Buy Rating Reiterated as FILSPARI Momentum Builds and Key Catalysts Approach; Price Target Unchanged at $67
Guggenheim Analyst forecast on DE:17R
Vamil Divan
Guggenheim
Guggenheim
€56.34→€65
Buy
96.98%
Upside
Reiterated
08/05/26
Travere Therapeutics price target raised to $75 from $65 at GuggenheimTravere Therapeutics price target raised to $75 from $65 at Guggenheim
Bank of America Securities Analyst forecast on DE:17R
Jason Zemansky
Bank of America Securities
Bank of America Securities
€61.54
Buy
86.47%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:17R
Tyler Van Buren
TD Cowen
TD Cowen
€52→€65
Buy
96.98%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on DE:17R
Allison Bratzel
Piper Sandler
Piper Sandler
€42.47
Buy
28.69%
Upside
Reiterated
06/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Elanco Animal Health (NYSE: ELAN), AbSci (NASDAQ: ABSI) and Travere Therapeutics (NASDAQ: TVTX)
Cantor Fitzgerald Analyst forecast on DE:17R
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
02/20/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY), UnitedHealth (NYSE: UNH) and Travere Therapeutics (NASDAQ: TVTX)
Leerink Partners Analyst forecast on DE:17R
Joseph Schwartz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
01/13/26
Leerink says Travere's Filspari PDUFA extension removes worst case scenario Leerink says Travere's Filspari PDUFA extension removes worst case scenario
Jefferies Analyst forecast on DE:17R
Maury Raycroft
Jefferies
Jefferies
€30.33
Buy
-8.08%
Downside
Reiterated
09/10/25
AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Travere Therapeutics

3 Months
Jason ZemanskyBank of America Securities
Success Rate
15/20 ratings generated profit
75%
Average Return
+28.36%
Copying Jason Zemansky's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +28.36% per trade.
1 Year
Jason ZemanskyBank of America Securities
Success Rate
19/20 ratings generated profit
95%
Average Return
+90.98%
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +90.98% per trade.
2 Years
Tyler Van BurenTD Cowen
Success Rate
20/21 ratings generated profit
95%
Average Return
+164.23%
Copying Tyler Van Buren's trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +164.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

17R Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
2
1
0
0
Buy
23
30
42
34
32
Hold
3
2
2
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
34
45
35
34
In the current month, 17R has received 32 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 17R average Analyst price target in the past 3 months is 63.34.
Each month's total comprises the sum of three months' worth of ratings.

17R Financial Forecast

17R Earnings Forecast

Next quarter’s earnings estimate for 17R is €0.02 with a range of -€0.82 to €0.73. The previous quarter’s EPS was -€0.32. 17R beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 17R has Performed in-line its overall industry.
Next quarter’s earnings estimate for 17R is €0.02 with a range of -€0.82 to €0.73. The previous quarter’s EPS was -€0.32. 17R beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 17R has Performed in-line its overall industry.

17R Sales Forecast

Next quarter’s sales forecast for 17R is €169.75M with a range of €136.40M to €208.22M. The previous quarter’s sales results were €147.15M. 17R beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 17R has Performed in-line its overall industry.
Next quarter’s sales forecast for 17R is €169.75M with a range of €136.40M to €208.22M. The previous quarter’s sales results were €147.15M. 17R beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 17R has Performed in-line its overall industry.

17R Stock Forecast FAQ

What is DE:17R’s average 12-month price target, according to analysts?
Based on analyst ratings, Travere Therapeutics’s 12-month average price target is 63.34.
    What is DE:17R’s upside potential, based on the analysts’ average price target?
    Travere Therapeutics has 91.94% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Travere Therapeutics a Buy, Sell or Hold?
          Travere Therapeutics has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Travere Therapeutics’s share price target?
            The average share price target for Travere Therapeutics is 63.34. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €78.00 ,and the lowest forecast is €42.47. The average share price target represents 91.94% Increase from the current price of €33.
              What do analysts say about Travere Therapeutics?
              Travere Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Travere Therapeutics?
                To buy shares of DE:17R, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.